Overview of the changing paradigm in cancer treatment: Oral chemotherapy

被引:108
作者
Aisner, Joseph
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA
[2] Canc Inst New Jersey, New Brunswick, NJ 08903 USA
关键词
antineoplastic agents; compliance; costs; drug administration routes; drug interactions; drugs; availability; fluorouracil; food; mechanism of action; neoplasms; patients; pharmacokinetics; quality of life; site of action; toxicity;
D O I
10.2146/ajhp070035
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Several new oral chemotherapeutic agents have recently been introduced. Many possess novel mechanisms of action and specific targets that result in different adverse effect profiles from those associated with traditional chemotherapies and hormonal therapies. The potential advantages and challenges associated with oral chemotherapy are discussed. Summary. Use of the oral route is convenient and allows administration to take place at home or in non-traditional settings. However, nausea, difficulty swallowing, patient nonadherence, interactions with drugs and food, other pharmacokinetic factors, and the high cost of treatment can present problems in using these agents by the oral route. Awareness by clinicians of the potential problems with oral chemotherapy can help to avoid or minimize problems that might affect patient outcomes. Conclusion. While bioavailability studies are often an integral part of developing oral agents, their comparisons with parenteral forms are less well documented. However, studies comparing intravenous 5-fluorouracil (5-FU) with oral 5-FU prodrugs have demonstrated that efficacy, safety, and quality of life are not compromised by the use of oral therapy. Finally, these studies, as well as others, reveal patients prefer the oral route of administration.
引用
收藏
页码:S4 / S7
页数:4
相关论文
共 22 条
[1]  
*AMG INC, 2006, VECT PACK INS
[2]  
[Anonymous], CLIN PRACT GUID ONC
[3]  
Avastin&REG
[4]  
, 2006, AV PACK INS
[5]   Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].
Blower, P ;
de Wit, R ;
Goodin, S ;
Aapro, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142
[6]  
BORNER M, 2000, P AM SOC CLIN ONCOL, V19
[7]  
*BRIST MYERS SQUIB, 2006, SPRYC PACK INS
[8]  
*CELG CORP, 2006, REVL PACK INS
[9]  
*CELG CORP, 2006, THAL PACK INS
[10]   Gender differences in p-glycoprotein:: Drug toxicity and response [J].
Davis, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6439-6440